RedHill Biopharma is dedicated to the development and commercialization in the U.S. of proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer



Commercial Products

RedHill has assembled an experienced specialty GI commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes four gastrointestinal specialty products in select U.S. territories: 

Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide) – prescription drug

Mytesi® (crofelemer 125 mg delayed-release tablets) – prescription drug

Esomeprazole Strontium Delayed-Release Capsules 49.3 mg – prescription drug 

EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) – medical food


Development Pipeline 

RedHill's pipeline of  late-stage, proprietary development programs includes three Phase III programs for gastrointestinal disease, as well as several Phase II programs in oncology and gastrointestinal diseases. 


Please see RedHill Biopharma's expanded acceess program here.